KISIMA-OVA

KISIMA-OVA is a therapeutic cancer vaccine candidate developed using the KISIMA platform technology, originally by AMAL Therapeutics (now part of Boehringer Ingelheim). It is a recombinant fusion protein designed to elicit a robust and targeted cytotoxic T-cell response. The construct comprises three functional components: a cell-penetrating peptide (CPP) derived from the ZEBRA protein for efficient intracellular delivery, a multi-antigenic cargo containing the model antigen ovalbumin (OVA), and a Toll-like receptor (TLR) peptide agonist that serves as a built-in adjuvant. By delivering antigens directly to dendritic cells and simultaneously providing maturation signals, KISIMA-OVA promotes the expansion of antigen-specific CD8+ T cells. While primarily used as a proof-of-concept tool in preclinical oncology models, it demonstrates the modularity and immunogenicity of the KISIMA platform, which is being applied to clinical candidates such as ATP128 for colorectal cancer.

Other names

KISIMA-Ovalbumin